| Male | Female | |||||||
| Total (n = 32) | Group H (n = 16) | Group L (n = 16) | p value (H vs L) | Total (n = 20) | Group H (n = 10) | Group L (n = 10) | p value (H vs L) | |
| Donor factors |
|
|
|
| ||||
| Sex (Male/Female) (N) | 12/20 | 5/11 | 7/9 | 0.465 | 14/6 | 6/4 | 8/2 | 0.628 |
| Age (years) | 57.0 ± 10.8 | 58.0 ± 10.5 | 56.1 ± 11.3. | 0.569 | 58.1 ± 7.5 | 58.0 ± 8.4 | 58.1 ± 7.0 | 0.977 |
| eGFR (mL/min/1.73 m2) | 103 [88 - 123] | 106 ± 23 | 111 ± 22 | 0.948 | 120 ± 18 | 119 ± 17 | 122 ± 19 | 0.743 |
| Recipient factors |
|
|
|
| ||||
| Age (years) | 46.3 ± 14.2 | 43.8 ± 13.1 | 48.8 ± 15.1 | 0.516 | 47.9 ± 14.6 | 48.6 ± 16.8 | 47.2 ± 12.9 | 0.837 |
| Dialysis history (months) | 20 [14 - 41] | 21 [14 - 38] | 20 [14 - 49] | 0.827 | 21 [10 - 53] | 36 ± 17 | 13 [7 - 71] | 0.205 |
| Operative time (hours) | 4.2 [3.3 - 4.5] | 4.1 [3.3 - 4.8] | 4.2 [3.7 - 4.5] | 0.706 | 4.0 [3.5 - 4.8] | 4.4 [3.5 - 5.0] | 3.8 [3.5 - 4.1] | 0.256 |
| Hemorrhage volume (mL) | 179 ± 127 | 211 ± 147 | 146 ± 96 | 0.120 | 180 [111 - 353] | 240 [150 - 403] | 167 ± 141 | 0.069 |
| Serum Cr concentrations (mg/dL) | 10.71 ± 3.88 | 10.19 ± 3.44 | 11.24 ± 4.33 | 0.119 | 8.03 ± 2.98 | 7.63 ± 2.97 | 8.43 ± 3.10 | 0.564 |
| BMI (kg/m2) | 24.3 ± 4.2 | 25.3 ± 4.6 | 23.3 ± 3.6 | 0.708 | 22.4 [17.5 - 26.3] | 25.6 ± 4.4 | 17.8 [17.3 - 23.5] | 0.004 |
| Primary disease (N) |
|
|
|
| ||||
| Chronic nephritic syndrome | 16 (50) | 9 (56) | 7 (44) | 0.723 | 12 (60) | 5 (50) | 7 (70) | 0.325 |
| IgA nephropathy | 4 (13) | 3 (19) | 1 (6) | 0.285 | 3 (15) | 1 (5) | 2 (20) | 0.500 |
| Mesangial proliferative glomerulonephritis | 1 (3) | 0 (0) | 1 (6) | 0.500 | 0 (0) | 0 (0) | 0 (0) | － |
| Nephrosclerosis | 0 (0) | 0 (0) | 0 (0) | － | 2 (10) | 2 (20) | 0 (0) | 0.237 |
| Focal glomerulonephritis | 2 (6) | 1 (6) | 1 (6) | 0.758 | 0 (0) | 0 (0) | 0 (0) | － |
| Lupus nephritis | 0 (0) | 0 (0) | 0 (0) | － | 1 (5) | 0 (0) | 1 (5) | 0.500 |
| Not clear | 9 (28) | 5 (31) | 4 (25) | 0.500 | 6 (30) | 2 (20) | 4 (40) | 0.314 |
| Diabetic nephropathy | 10 (31) | 6 (38) | 4 (25) | 0.446 | 4 (20) | 3 (30) | 1 (10) | 0.291 |
| ANCA-associated glomerulonephritis | 0 (0) | 0 (0) | 0 (0) | － | 2 (10) | 2 (20) | 0 (0) | 0.237 |
| Autosomal dominant polycystic kidney disease | 3 (9) | 0 (0) | 3 (19) | 0.242 | 1 (5) | 0 (0) | 1 (10) | 0.500 |
| APRT deficiency | 1 (3) | 1 (6) | 0 (0) | 0.500 | 0 (0) | 0 (0) | 0 (0) | － |
| Alport syndrome | 1 (3) | 0 (0) | 1 (6) | 0.500 | 0 (0) | 0 (0) | 0 (0) | － |
| Behcet’s disease | 0 (0) | 0 (0) | 0 (0) | － | 1 (5) | 0 (0) | 1 (10) | 0.500 |
| Drug-induced nephropathy | 1 (3) | 0 (0) | 1 (6) | 0.500 | 0 (0) | 0 (0) | 0 (0) | － |